Hormonal IUD Shows Promise as an Effective Treatment for Early Endometrial Cancer or Precancer
March 22nd 2021According to study results presented at the SGO meeting, biopsies showed no signs of cancer or precancer in two-thirds of 165 women with stage I endometrial cancer or atypical endometrial hyperplasia, 6 months after insertion of the hormonal IUD.
Read More
Pharmacy Focus Episode 20: Medication Misuse and The Future of Pharmacy in 2021
March 19th 2021The Pharmacy Times® Pharmacy Focus podcast provides the latest industry news and information, thought-leader insights, clinical updates, patient counseling tools, and innovative solutions for the everyday practice and business of pharmacy.
Listen
CDC Analysis Finds Most People Receive Second COVID-19 Shot on Time
March 18th 2021Health care professionals should address potential barriers to completing the COVID-19 vaccination series, including scheduling second-dose appointments at the first-dose administration and sending reminders for second-dose visits.
Read More
Clinical Trial Confirms Nasal Spray Efficacy in Treating, Reducing Transmission of COVID-19
March 18th 2021Results of clinical trials have shown that a nitric oxide nasal spray is both a safe and effective antiviral treatment to prevent COVID-19 transmission and symptom duration, as well as reduce symptom severity and damage in those already infected.
Read More
Pandemic Stress Leading to Unhealthy Changes in Weight, Increased Drinking
March 18th 2021Adults in the United States are reporting undesired weight changes, an increase in drinking, and other negative behavior changes that may be unhealthy coping mechanisms for prolonged stress, according to a survey conducted by the American Psychological Association (APA).
Read More
Counseling Patients on Proper Use of CBD Products
March 17th 2021With a wide array of cannabidiol (CBD) and CBD extract products available without a prescription, pharmacists have an increasingly important role to play in counseling patients on which products may work for them and how they should be properly used.
Read More
FDA Grants MK-6482 NDA Priority Review for von Hippel-Lindau Disease-Associated RCC
March 17th 2021The FDA has granted priority review for an NDA for the hypoxia-inducible factor-2 alpha inhibitor MK-6482 for the potential treatment of patients with von Hippel-Lindau disease-associated renal cell carcinoma that does not require immediate surgery.
Read More